Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Martin Bergman, MD

self
Ridley Park, PA, United States

Dr. Bergman received his medical degree from the Medical College of Wisconsin, after beginning his studies at the University of L’Aquila, Italy. He completed his Internal Medicine Residency and Rheumatology Fellowship at the Medical College of Pennsylvania. Dr. Bergman has worked as a solo practitioner since 1987, while maintaining his academic medicine position, eventually attaining the rank of Clinical Professor at Drexel University College of Medicine. For the body of his work, Dr. Bergman was elected as a Fellow of the College of Physicians of Philadelphia, America’s oldest medical society.
Collaborating with others, Dr. Bergman played an instrumental role in the development of the RAPID3, now a widely used, and ACR recognized, disease activity measurement tool. He was a member of the International Treat to Target Task Force, which promoted the use of metrics in the treatment of RA. Based on his clinical experience and expertise in disease activity measurement, Dr. Bergman is an active lecturer, both in the United States and internationally. Another priority is inspiring and developing interest in the field of Rheumatology among Medical Residents, with over 10 of his students going on to pursue a career in our specialty.
As a member of the ACR, Dr. Bergman presented as a “Meet the Professor” at multiple annual meetings, has been a Moderator at clinical poster sessions, and has served as a member of the ACR Subcommittee on Quality Measures.

Presentation(s):

  • 12S162: Abstracts: Patient Outcomes, Preferences, & Attitudes I: Assessment Tools (0823–0828)

    Sunday, November 12, 2023
    4:00 PM – 5:30 PM PT

    Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Amgen: Consultant (Ongoing); GlaxoSmithKlein(GSK): Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); JNJ (Janssen): Shareholder (Ongoing); Merck/MSD: Shareholder (Ongoing); Pfizer: Consultant (Ongoing); Regneron: Consultant (Ongoing); Sanofi: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)